Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 19.69 0.75 (3.96%) Market Cap: 1.68 Bil Enterprise Value: 1.18 Bil PE Ratio: 0 PB Ratio: 3.85 GF Score: 41/100

Q4 2020 Syndax Pharmaceuticals Inc Earnings Call Transcript

Mar 08, 2021 / 09:30PM GMT
Release Date Price: $23.3 (-1.19%)
Operator

Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2020 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Ms. Maghan Meyers of Argot Partners. Please begin.

Maghan Meyers

Welcome, and thank you to those of you joining us on the line and the webcast this afternoon, for a review of Syndax's fourth quarter 2020 financial and operating results. I'm Maghan Meyers with Argot Partners, and with me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; Daphne Karydas, Chief Financial Officer.

Also joining us on the call today for the question-and-answer session is Michael Metzger, President and COO; Dr. Michael Meyers, Chief Medical Officer; and Dr. Peter Ordentlich, Chief Scientific Officer.

This call is being accompanied by a slide deck that has been posted to the company's website, so I would ask you to please turn to our forward-looking statements on Slide 2.

Before we begin, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot